This study aims at investigation of the caregiver burden of Wet Age-related Macular Degeneration (wAMD) patients and at the assessment of how much of caregiver burden could be reduced in transitioning from Pro Re Nata to proactive therapy especially in real-life rural settings where public transportations are not readily available.
Study Type
OBSERVATIONAL
Enrollment
72
Anti-VEGF therapy following the Summary of Product Characteristics
Unnamed facility
Many Locations, Japan
Degree of caregiving burden on caregivers (BIC-11)
Burden Index of Caregivers (BIC), a multidimensional short care burden scale from Japan.The score range is from 0-40, with high scores indicating greater care giver burden.
Time frame: At enrollment
Relationship between BIC-11 and the number of hospital visits for wAMD treatments
Time frame: Up to 1 year
Frequency of hospital visits
Time frame: Up to 1 year
Time spent by accompanying caregivers for a clinic visit for wAMD management (minutes)
Time frame: Up to 1 year
Estimated costs spent by accompanying caregivers on hospital visits for wAMD management
Time frame: Up to 1 year
Level of depression among caregivers (CES-D)
CES-D will be applied to determine depression.The score range is from 0 to 60, with high score indicating greater depressive symptoms. Cut off score is 16 or greater in Japan to assess whether individuals experience depression.
Time frame: At Enrollment
Types of treatments for wAMD
Anti-VEGF(anti vascular endothelial growth factor)drugs, laser therapy, Photodynamic Therapy,etc.
Time frame: At Baseline
Frequency of treatments
Number of a therapeutic agent given to patients
Time frame: At baseline
Length of treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Duration of a therapeutic agent received
Time frame: At baseline
Dosing schedule
The schedule of doses of a therapeutic agent per unit of time
Time frame: At baseline
Percentage of patients accompanied by primary caregivers
Time frame: At baseline